Cover Image
市場調查報告書

全球老年癡呆症治療藥市場

Global Alzheimer's Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 273286
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
全球老年癡呆症治療藥市場 Global Alzheimer's Drugs Market 2014-2018
出版日期: 2014年06月20日 內容資訊: 英文 108 Pages
簡介

老年癡呆症,許多65歲以上的人發病,還有女性比男性容易罹患。全球現在有3500萬人以上發病,不過這個數字,預測2030年將成為2倍。全球老年癡呆症治療藥市場,預計從2013年到2018年,以2.61%的年複合成長率(CAGR)擴大。

本報告提供全球老年癡呆症治療藥市場現狀及其成長預測、主要醫藥品的評估、供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 癡呆症
  • 流行病學及預測
  • 癡呆症的種類

第7章 老年癡呆症

  • 全球情形
  • 病因
  • 治療費
  • 老年癡呆症與看護

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各作用機制的市場區隔

  • AChE抑制劑
  • 麩胺酸抑制劑

第10章 主要藥物的市場評估

  • Aricept
  • Exelon
  • Namenda
  • Radazyne

第11章 主要藥物的競爭力評估

第12章 老年癡呆症的研究

  • 美國老年癡呆症計劃法(National Alzheimer's Project Act:NAPA)
  • 臨床實驗平台

第13章 地理區分

第14章 購買標準

第15章 市場成長因素

第16章 成長因素與其影響

第17章 市場課題

第18章 成長因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
    • 主要消息
  • 市場佔有率分析

第22章 預計將來會進入市場的供應商

第23章 主要供應商分析

  • Eisai
  • Forest Laboratories Inc.
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

第24章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR3675

About Alzheimer's Disease

Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.

TechNavio's analysts forecast the Global Alzheimer's Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Alzheimer's Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer's Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eisai Co., Ltd.
  • Forest Laboratories Inc.
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

Other Prominent Vendors

  • Adamas Pharmaceuticals Inc.
  • Archer Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Merck & Co., Inc.
  • MorphoSys AG
  • Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • TauRx Pharmaceuticals Ltd.
  • Zinfandel Pharmaceuticals Inc.

Key Market Driver

  • Increasing Aging Population

For a full, detailed list, view our report

Key Market Challenge

  • Poor Diagnosis of Alzheimer's Disease

For a full, detailed list, view our report

Key Market Trend

  • Increasing Incidence, Prevalence, and Mortality of Alzheimer's Disease

For a full, detailed list, view our report

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Dementia
  • 06.2. Epidemiology & Forecast (2013-2018)
  • 06.3. Types of Dementia

07. Alzheimer's Disease

  • 07.1. A Global Burden
  • 07.2. Etiology
  • 07.3. Cost of Care
  • 07.4. Alzheimer's Disease & Caregiving

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by MOA

  • 09.1.1. AChE Inhibitors
  • 09.1.2. Glutamate Inhibitors

10. Market Assessment of Top Drugs

  • 10.1. Aricept
    • 10.1.1. Sales
    • 10.1.2. Key Regulatory Approvals and Agreements
    • 10.1.3. US Spending by Various Channels 2010-2013
  • 10.2. Exelon
    • 10.2.1. Sales
    • 10.2.2. Key Regulatory Approvals and Agreements
    • 10.2.3. US Spending by Various Channels 2010-2013
  • 10.3. Namenda
    • 10.3.1. Sales
    • 10.3.2. Key Regulatory Approvals and Agreements
    • 10.3.3. US Spending by Various Channels 2010-2013
  • 10.4. Radazyne
    • 10.4.1. Sales
    • 10.4.2. Key Regulatory Approvals and Agreements

11. Competitive Assessment of Top Drugs

12. Focus on Alzheimer's Research

  • 12.1. National Alzheimer's Project Act
  • 12.2. Clinical Pipeline

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
  • 21.2. Market Share Analysis 2013

22. Future Vendors Expected To Tap the Market

23. Key Vendor Analysis

  • 23.1. Eisai Co., Ltd.
    • 23.1.1. Key Facts
    • 23.1.2. Business Overview
    • 23.1.3. Sales by Geography
    • 23.1.4. Revenue Comparison
    • 23.1.5. Sales by Geography
    • 23.1.6. Business Strategy
    • 23.1.7. Key Information
    • 23.1.8. SWOT Analysis
    • 23.1.9. Strengths
    • 23.1.10. Weaknesses
    • 23.1.11. Opportunities
    • 23.1.12. Threats
  • 23.2. Forest Laboratories Inc.
    • 23.2.1. Key Facts
    • 23.2.2. Business Overview
    • 23.2.3. Business/Product Segmentation
    • 23.2.4. Product Segmentation by Revenue 2013
    • 23.2.5. Business/Products Segmentation by Revenue 2012 and 2013
    • 23.2.6. Sales by Geography
    • 23.2.7. Business Strategy
    • 23.2.8. Key Information
    • 23.2.9. SWOT Analysis
    • 23.2.10. Strengths
    • 23.2.11. Weaknesses
    • 23.2.12. Opportunities
    • 23.2.13. Threats
  • 23.3. Janssen Pharmaceuticals Inc.
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Product Segmentation
    • 23.3.4. Business Strategy
    • 23.3.5. Key Information
    • 23.3.6. SWOT Analysis
    • 23.3.7. Strengths
    • 23.3.8. Weaknesses
    • 23.3.9. Opportunities
    • 23.3.10. Threats
  • 23.4. Novartis AG
    • 23.4.1. Key Facts
    • 23.4.2. Business Description
    • 23.4.3. Business Segmentation
    • 23.4.4. Revenue by Business Segmentation
    • 23.4.5. Revenue Comparison 2012 and 2013
    • 23.4.6. Sales by Geography
    • 23.4.7. Business Strategy
    • 23.4.8. Key Developments
    • 23.4.9. SWOT Analysis
    • 23.4.10. Strengths
    • 23.4.11. Weaknesses
    • 23.4.12. Opportunities
    • 23.4.13. Threats

24. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Projected Prevalence of Dementia by Regions 2013-2050 (in millions)
  • Exhibit 3: Projected Prevalence of Dementia by Regions 2013-2018 (in millions)
  • Exhibit 4: Types of Dementia by Prevalence 2013
  • Exhibit 5: Alzheimer's Disease and Other Dementias Burden by Geographical Segmentation (Annually) 2013
  • Exhibit 6: Costs of Care by Payer for Americans Age 65 and Older with Alzheimer's Disease and Other Dementias 2013
  • Exhibit 7: Distribution of Alzheimer's Caregivers by Age, 2013
  • Exhibit 8: Projected Prevalence of dependence in 2030 (in percent)
  • Exhibit 9: Global Alzheimer's Disease Drugs Market 2013-2018 (US$ billion)
  • Exhibit 10: Global Alzheimer's Drugs Market Segmentation by MOA
  • Exhibit 11: Eisai Co. Ltd.'s Aricept Revenue FY1996-FY2013 (US$ million)
  • Exhibit 12: Eisai Co. Ltd.'s Aricept Geography-wise Revenue FY1996-FY2010 (US$ million)
  • Exhibit 13: Eisai Co. Ltd.'s Aricept Geography-wise Revenue FY2011-FY2013 (US$ million)
  • Exhibit 14: Key Event Timeline of Aricept Formulations
  • Exhibit 15: Timeline for Aricept Formulations in US and Europe
  • Exhibit 16: US Spending on Aricept by Various Channels 2010-2013
  • Exhibit 17: Novartis AG's Exelon Revenue 2001-2013 (US$ million)
  • Exhibit 18: Novartis AG's Exelon Geography-Wise Revenue 2001-2013 (US$ million)
  • Exhibit 19: Key Event Timeline of Exelon Formulations
  • Exhibit 20: US Spending on Exelon by Various Channels 2010-2013
  • Exhibit 21: Forest's Namenda Revenue 2004-2014 (FY ending March 2014) (US$ million)
  • Exhibit 22: Key Event Timeline of Namenda Formulations
  • Exhibit 23: US Spending on Namenda by Various Channels 2010-2013
  • Exhibit 24: Razadyne Revenue 2007-2009 (US$ million)
  • Exhibit 25: Key Event Timeline of Razadyne
  • Exhibit 26: Sales of Top 3 Alzheimer's Drugs FY 2004-2013 (US$ million)
  • Exhibit 27: Sales of Top 3 Alzheimer's Drugs 2004-2013 (US$ million)
  • Exhibit 28: Alzheimer's Disease Research Projects by NIH Institutes and Centers 2011
  • Exhibit 29: NIH funded Alzheimer's Disease Research Projects by CADRO topic 2011
  • Exhibit 30: Classification of Disease Modifying Pipeline Molecules by MOA
  • Exhibit 31: Clinical Trials of Alzheimer's Disease by Phase 2013
  • Exhibit 32: Clinical Trials of Alzheimer's Disease by Recruitment Status 2013
  • Exhibit 33: Promising Late Stage Pipeline Molecules 2013
  • Exhibit 34: Global Alzheimer's Drugs market by Geographical Segmentation 2013
  • Exhibit 35: 65+ Global Population 2014-2018 (in million)
  • Exhibit 36: Global Alzheimer's Drugs Market Share Analysis 2013
  • Exhibit 37: Eisai Co., Ltd.: Geographical Segmentation of Revenue for 2013 and 2012(US$ billion)
  • Exhibit 38: Eisai Co., Ltd.: Revenue comparison for the last 3 years (US$ billion)
  • Exhibit 39: Eisai Co., Ltd.: Sales by Geography for 2013 (US$ billion)
  • Exhibit 40: Forest Laboratories Inc.: Product Segmentation (by therapeutic areas) 2013
  • Exhibit 41: Forest Laboratories Inc.: Product Segmentation by Revenue 2013
  • Exhibit 42: Forest Laboratories Inc.: Product Segmentation by Revenue 2012 and 2013(US$ million)
  • Exhibit 43: Company Name: Sales by Geography 2013
  • Exhibit 44: Janssen Pharmaceuticals, Inc.: Product Segmentation 2013
  • Exhibit 45: Novartis AG: Business Segmentation
  • Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013
Back to Top